Treatment News : HIV Treatment During Primary Infection Raises CD4s—and Further Questions

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » January 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

January 22, 2013

HIV Treatment During Primary Infection Raises CD4s—and Further Questions


Two new studies, each published in The New England Journal of Medicine (NEJM), suggest that treating HIV with antiretrovirals (ARVs) within four to six months after infection helps raise CD4 counts, but neither study was able to make an overwhelming argument for starting therapy so early, JournalWATCH reports.

One study looked at acute or early HIV infections over a 48-month period in two cohorts of somewhat overlapping study participants: one group of 384 that was not receiving ARVs and a second group of 312 that began ARVs shortly after entering the study.  

The researchers found that, among those not taking HIV medications, CD4 levels tended to increase, from a median of 495 CD4 cells to 763, until about four months had passed following their estimated date of infection. Thereafter, CD4 levels declined steadily.  

Among those who began ARVs four months or earlier after infection, 64 percent reached 900 CD4 cells, compared with 34 percent of those who began medications more than four months after infection. The study also found that those who began ARVs after the four-month cutoff were 65 percent less likely to reach 900 CD4 cells and that their rate of CD4 cell recovery was 56 percent slower.  

The researchers concluded that CD4 cells drop after a four-mouth window following HIV infection and that beginning ARV therapy during this period “is associated with an enhanced likelihood of recovery of CD4 counts.”

A second study of adults living with HIV for less than six months randomly divided 366 participants into three groups: 123 took ARVs for 48 weeks then stopped, 120 for 12 weeks and stopped, and 123 took no ARVs. The study’s “primary end point” was the percentage of participants who reached a CD4 count of less than 350 or began ARVs (or started again, in the case of those who were in the active arms of the study).

With an average 4.2 years of follow-up, only those in the 48-week period cohort had a reduced likelihood of reaching the primary end point—with 29 percent reaching 350 CD4 cells, compared with about 40 percent for both other groups—although the researchers could not connect this difference to immune function. For those in the 48-week group, beginning treatment sooner after infection appeared more beneficial.

An accompanying editorial in NEJM by Bruce D. Walker, MD, and Martin S. Hirsch, MD, of Harvard Medical School states that both studies “provide evidence that greater CD4+ cell recovery is achieved with earlier initiation of therapy during primary infection, but both fall short of defining clear clinical benefit for such early treatment.”

To read the JournalWATCH report, click here.

To read the study on enhanced CD4 recovery with earlier ARV therapy, click here.

To read the study on short-course ARV therapy in primary HIV infection, click here.

To read the accompanying editorial,click here

Search: HIV, treatment, antiretroviral, early, ARV, The New England Journal of Medicine, NEJM, JournalWATCH, primary infection, CD4 cells, Bruce D. Walker, Martin S. Hirsch, Harvard Medical School.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


  comments 1 - 2 (of 2 total)    

Darnell, Chicago, 2013-01-23 14:28:44
I can agree with this article.

Theresa, Northbend, 2013-01-23 09:42:54
I was diagnosed within one month of being infected, I am going on 17 years living with hiv started meds within months of being infected and I have cared a cd4 cell count of 1300. testing and treatment is the key to living a healthy life

comments 1 - 2 (of 2 total)    


[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    chipper52
    Palm Springs
    California


    slimcuteguy
    Asheville
    North Carolina


    youngbloodlatino
    Columbia
    Maryland


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.